<DOC>
	<DOCNO>NCT00422565</DOCNO>
	<brief_summary>The trial follow primary objective : To compare safety effectiveness primary acute MI intervention ABT 578-eluting balloon expandable stent ( Medtronic , Minneapolis , MN ) vs. sirolimus-eluting balloon expandable stent ( Cordis Johnson &amp; Johnson , Warren , New Jersey ) vs. paclitaxel-eluting stent ( Taxus Liberte , Boston Scientific ) .</brief_summary>
	<brief_title>Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent Acute Myocardial Infarction Patients</brief_title>
	<detailed_description>Previous study document slow-release polymeric sirolimus-eluting stent ( Cypher , Cordis ) paclitaxel-eluting stent ( Taxus , Boston Scientific ) reduce neointimal formation result decrease angiographic restenosis target lesion revascularization 1-3 year multicenter randomized clinical trial RAVEL , SIRIUS , TAXUS I-VI . From study , two lead drug-eluting stent ( DESs ) Cypher Taxus widely rapidly accepted standard treatment coronary lesion . Recently , randomized study conduct reveal different outcome different two DESs . These study show sirolimus-eluting stent well paclitaxel-eluting stent term low angiographic restenosis rate two DESs similar angiographic outcome . A recent meta-analysis support result former randomized study . Patients receive sirolimus-eluting stent significantly low risk restenosis target vessel revascularization compare receive paclitaxel-eluting stent . With recent approval new DES , ABT-578-eluting stent ( Endeavor , Medtronic , Minneapolis , MN ) , comparison study conduct compare Endeavor ABT-578-eluting stent sirolimus-eluting stent paclitaxel-eluting stent . The ENDEAVOR clinical trial currently progress evaluate phosphoryl choline ( PC ) -coated ABT-578-eluting stent prevention restenosis . Angiographic analysis 4 month 100-patient focal de novo lesion ENDEAVOR I feasibility study demonstrate mean in-stent percent diameter stenosis approximately 14 % late lumen loss 0.3 mm low frequency target lesion revascularization ( 1 % ) . The clinical outcome ENDEAVOR II ( 1,197 patient randomize ABT-578 bare metal stent ) show superior efficacy PC-coated ABT-578-eluting stent bare-metal stent . In patient acute myocardial infraction ( MI ) , routine stent implantation show well procedural success rate clinical outcome balloon angioplasty [ 11 ] . However , restenosis vessel reocclusion remain major challenge limit long-term success percutaneous treatment . In clinical study 400 patient stent implantation acute MI , angiographic restenosis occur 31 % , considerably expect patient stable coronary disease . There little information available efficacy long-term safety DES acute MI . The result several registry randomize trial ( Cypher-AMI , Typhoon , PASSION ) demonstrate short-term long-term safety efficacy DES compare BMS . The incomplete evidence date implantation SES patient Acute MI safe effective BMS result implantation PES variance result BMS . However , date , randomize trial compare efficacy safety among commonly use DES ( zotarolimus- vs. sirolimus- vs. paclitaxel-eluting stent ) treatment acute MI patient . The result large randomized trial large registry allow u make evidence-based decision stent use patient acute MI . Therefore , design randomize , control , partially blind trial compare safety efficacy zotarolimus vs. sirolimus vs. paclitaxel stent acute MI patient undergo percutaneous coronary intervention .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . The patient must least 18 year age . 2 . Culprit de novo lesion native coronary artery significant stenosis ( &gt; 50 % visual estimate ) eligible stent implantation ( limitation stent length ) 3 . Prolonged , continuous ( ≥ 20 min ) chest pain despite nitrate : ( 1 ) least 1mm STsegment elevation least 2 lead reciprocal STsegment depression ≥ 2 contiguous precordial lead , ( 2 ) newly develop leave bundle branch block 4 . Symptoms &lt; 12 hour 5 . The patient guardian agrees study protocol schedule clinical angiographic followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . 1 . The patient know hypersensitivity contraindication follow medication : Heparin Aspirin Both Clopidogrel TIclopidine Sirolimus , paclitaxel , ABT 578 Stainless steel and/or Contrast medium ( patient document sensitivity contrast effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Patients true anaphylaxis prior contrast medium , however , enrol ) . 2 . Systemic ( intravenous ) Sirolimus , paclitaxel ABT578 use within 12 month . 3 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 4 . History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . 5 . Fibrinolytic therapy current MI treatment 6 . Previous coronary intervention target vessel 7 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 8 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 9 . Previously document LVEF &lt; 30 % . 10 . Evident cardiogenic shock randomization 11 . Patients leave main stem stenosis ( &gt; 50 % visual estimate ) 12 . Severe calcification tortuosity 13 . Multivessel disease nonculprit vessel require bypass surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Stent</keyword>
	<keyword>Myocardial Infarction</keyword>
</DOC>